IUGNF News and Press, Imugene Ltd

(NewsDirect) Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong sits down with Proactive’s Jonathan Jackson to discuss the strategic partnership the company has formed with Kincell Bio, LLC that involves the sale of Imugene's Current Good Manufacturing Practice (CGMP) complia...

The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma) Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers, particularly in cholangiocarcinoma where one patient treated with CF33-hNIS (VAXINIA) achieve...

(NewsDirect) Imugene Ltd (ASX:IMU) CEO Leslie Chong sits down with Proactive’s Jonathan Jackson to discuss enrolment for a pivotal expansion study targeting bile tract cancer (cholangiocarcinoma) patients. This follows the successful completion of the fifth high-dose cohort in the intr...

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients. Encouraging VAXINIA efficacy, including a complete response (CR) and two partial responses (PRs), has warranted cohort expansions in biliary tract cancer and othe...

(NewsDirect) Imugene Ltd (ASX:IMU) CEO Leslie Chong joins Proactive’s Jonathan Jackson in the Proactive studio to discuss how the company has advanced its Phase 1 onCARlytics solid tumour trial to combination arm treatment. The trial, known as OASIS, focuses on adult patients with adva...

The OASIS trial is a first-in-class clinical trial combining a CD19-expressing oncolytic virus, which flags solid tumours for attack by CD19-targeting therapeutics such as Amgen’s Blincyto ® , Gilead’s Yescarta ® and Imugene’s own allogeneic CAR T Azer-cel ...

(NewsDirect) Imugene Ltd (ASX:IMU) CEO Leslie Chong sits down with Jonathan Jackson in the Proactive studio to delve into the company’s latest milestone - commencement of dosing for the first patient in the intravenous monotherapy arm of a Phase 1 clinical trial of the CD19 oncolytic v...

SYDNEY, AUSTRALIA / ACCESSWIRE / January 18, 2024 / Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce further details from its poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) currently being conducted in San Francisco. The p...

(NewsDirect) Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong tells Proactive the company is preparing 10 clinical trial sites in Australia and the UK for a new PD1-Vaxx Phase 2 colorectal (CRC) cancer clinical trial set to begin in 2024. The company intends to enrol 44 patients across the s...

(NewsDirect) Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong and chief medical officer Dr Paul Woodard speak with Proactive following the news it’s been granted 'Fast Track' designation from the US Food and Drug Administration (FDA) for its MAST (metastatic advanced solid tumours) cl...